drugset / Trial / NCT06675422

JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)

NCT06675422

NaSingle-groupOpen-labelTreatment

Summary

Early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of active systemic lupus erythematosus (SLE)

Timeline

Start
2024-10-09
Primary completion
2026-09-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject JY231 Cell therapy Intravenous